Skip to content

HEARAD

Active Private limited companyfounded 2022active for 4 yearsEglantierlaan 11, 2020 AntwerpKBO/BCE: BE 0790.612.455

Lifetime

3 annual accounts with figures on one time axis
peak of €787,453 in 2025
€787,453▲ 30.8%
peak of €460,565 in 2025
€460,565▲ 44.3%
peak of €870,073 in 2025
€870,073▲ 112%
€1.1m▲ 28.2%
Board1 name since 2022
1 director
Documentsfilings and deeds
01-07-202630 days before the deadline
2025abbreviated format
Gross margin from €602,080 to €787,453Result from €319,210 to €460,565Registered office moved within Antwerp 28-02Equity from €409,507 to €870,073Debts from €830,300 to €1.1mCash from €178,054 to €437,573

Key points

from the 2025 annual accounts

Equity

€870,073 ▲ 112%
€410,0002024€870,0002025

Equity rose in 2025 from €409,507 to €870,073.

Turnover

≈ €1.2m estimated

The accounts state no turnover.

Investments

€796 0.0 times depreciation
202320242025

Green is investment, beige is depreciation.

Liquidity

6.69 was 2.86 in 2024

Short-term debts rose from €215,552 to €218,903.

Filings

3 annual accounts 2 late
AprilJune31 JulyOctober202320242025

The 2024 accounts came in latest, 29 days after the end of the period.

Position in the sector

€460,565

Higher net result than 85% of companies in human health. Sector median €125,318 · 2,768 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,137 companies had the same profile as HEARAD has now. Each dot stands for 8 companies, two years later.

96.9%
were still trading
2.1%
stopped another way
0.8%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,137 companies, not a prediction for HEARAD. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 12-09-2022
Board & ownership

Recent changes

Registered office moved within Antwerp The registered office moved from De Beuckerstraat 33, 2018 Antwerpen to Eglantierlaan 11, 2020 Antwerpen · Board meeting of 27-12-2024 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0790612455
First establishment At the time the registered office was still in Antwerpen, De Beuckerstraat 33.
Incorporation Founding capital of €2,000, 100 shares · Founded by (founder and shareholder) · appointed as director · published on 12-09-2022 · Gazette deed
All 12 events

Comparable companies

same main activity, similar in size and age
Company
HEARAD Antwerp €1.9m €787,453 45.0% -
Oogarts Dr. K. Verbruggen Mechelen €1.8m €641,706 57.6% -
Antwerp Eye Care Antwerp €1.8m €637,581 83.5% -
Maki - Invest Duffel €1.8m €622,324 0.2% -
CKMS Hasselt €1.7m €727,193 59.0% -
X-RAYS MEDICAL Beyne-Heusay €2.1m €869,782 95.6% -
Dr. Frédéric Vanhove Nazareth-De Pinte €1.5m €773,196 87.5% -

These companies have the same main activity as HEARAD: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.5m and €2.1m, founded between 2021 and 2023.

Official details

Source: KBO
Status
Active since 08-09-2022Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.336.669.4242020 Antwerp, registered on 01-10-2022
Financial year end
31 December
Peppol
Reachable since 24-11-2023
Company details

Annual accounts 2025

€1.9m▲ 56.1%
Filing
Filed on 01-07-2026, 30 days before the end of the filing period
Financials

Insights on HEARAD

HEARAD files the abbreviated format. That format states no turnover. The gross margin rose from €135,489 in 2023 to €787,453 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about HEARAD

What is the company number of HEARAD?
The company number of HEARAD is 0790.612.455. The VAT number is the same number with BE in front: BE 0790.612.455.
Where is HEARAD based?
The registered office is at Eglantierlaan 11, 2020 Antwerp.Company details
What does HEARAD do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of HEARAD?
HEARAD is a private limited company (BV).
When was HEARAD founded?
HEARAD was founded on 08-09-2022.
Is HEARAD still active?
Yes, HEARAD is an active enterprise in the KBO register.
What is the turnover of HEARAD?
The turnover in financial year 2025 is ≈ €1.2m. This figure is estimated from the gross margin of €787,453 and 31 comparable companies (NACE 86220). It probably lies between €1.0m and €1.6m.Financials
Is HEARAD profitable?
In financial year 2025, HEARAD made a profit of €460,565.
Where can I find the annual accounts of HEARAD?
HEARAD filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of HEARAD due?
HEARAD must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.